New investigational PCSK9 inhibitor shown to significantly reduce LDL-C among Japanese patients
BRIDGEWATER, NJ and TARRYTOWN, NY, USA I April 1, 2014 I Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the first Phase 2 study with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), in Japanese patients met its primary endpoint. The results demonstrated that the mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) percentage reduction from baseline to week 12, the primary efficacy endpoint of the study, was significantly greater in patients randomized to receive one of three doses of alirocumab administered every other week (Q2W) — 150 milligrams (mg), 75 mg, and 50 mg, in combination with statin therapy, compared to patients receiving placebo.
At Week 12, the mean percentage reduction in LDL-C from baseline in patients receiving alirocumab 50 mg Q2W was 55 percent, alirocumab 75 mg Q2W was 62 percent and alirocumab 150 mg Q2W was 72 percent, compared to 3 percent in the placebo group (p
Treatment emergent adverse events (TEAEs) in this study were reported by 52 percent of patients in the alirocumab 50 mg group, 48 percent of patients in the 75 mg group, 64 percent of patients in the 150 mg group, compared to 32 percent in the placebo group. The most frequently reported TEAEs were nasopharyngitis, injection site reaction, back pain, cystitis and ligament sprain.
“We are delighted with the findings from the first Phase 2 trial with alirocumab in Japanese patients. Not only was alirocumab shown, in this study, to significantly reduce LDL-C in this patient population, the results of this study also demonstrate the potential efficacy of alirocumab at a range of doses,” said Jay Edelberg M.D., Ph.D., Head of the PCSK9 Development and Launch Unit, Sanofi Group.
“Hypercholesterolemia is a growing problem in Japan and many patients are poorly-controlled on statins,” commented George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. “The results from this trial support the efficacy and safety of alirocumab at a range of doses in Japanese patients.”
About the Alirocumab Phase 2 Japanese Study
This multicenter, placebo-controlled Phase 2 study randomized approximately 100 patients with LDL-C greater than or equal to 100 mg/dL receiving lipid-modifying therapy. 25 patients per group were randomized to receive one of three doses of alirocumab dosed subcutaneously every other week (Q2W) — 150 milligrams (mg), 75 mg or 50 mg, or placebo, all in combination with statin therapy.
The primary study endpoint was the percentage change in calculated LDL-C from baseline to Week 12. The secondary study endpoints included absolute change in calculated LDL-C from baseline to Week 12 and percent and absolute changes in other lipid parameters at Week 12.
About PCSK9
PCSK9 is known to be a determinant of circulating LDL levels, as it binds to LDL receptors resulting in their degradation so that fewer are available on liver cells to remove excess LDL-C from the blood. Moreover, statins increase the level of circulating PCSK9, which in turn may reduce the density of LDL-C receptors available to clear LDL-C from the circulation. Blocking the PCSK9 pathway is therefore a potentially novel mechanism for lowering LDL-C.
About alirocumab
Alirocumab is an investigational, fully-human monoclonal antibody that targets and blocks PCSK9. It is administered via subcutaneous injection. By inhibiting PCSK9, a determinant of circulating LDL-C levels in the blood, alirocumab has been shown in pre-clinical studies to increase the number of LDL receptors on hepatocytes, thereby lowering LDL-C.
The investigational agent described above is currently under clinical development, and its safety and efficacy have not been fully evaluated by any regulatory authority.
About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (SAN) and in New York (SNY).
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York, that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, asthma, and atopic dermatitis. For additional information about the company, please visit www.regeneron.com.
SOURCE: Regeneron Pharmaceuticals
Post Views: 160
New investigational PCSK9 inhibitor shown to significantly reduce LDL-C among Japanese patients
BRIDGEWATER, NJ and TARRYTOWN, NY, USA I April 1, 2014 I Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the first Phase 2 study with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), in Japanese patients met its primary endpoint. The results demonstrated that the mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) percentage reduction from baseline to week 12, the primary efficacy endpoint of the study, was significantly greater in patients randomized to receive one of three doses of alirocumab administered every other week (Q2W) — 150 milligrams (mg), 75 mg, and 50 mg, in combination with statin therapy, compared to patients receiving placebo.
At Week 12, the mean percentage reduction in LDL-C from baseline in patients receiving alirocumab 50 mg Q2W was 55 percent, alirocumab 75 mg Q2W was 62 percent and alirocumab 150 mg Q2W was 72 percent, compared to 3 percent in the placebo group (p
Treatment emergent adverse events (TEAEs) in this study were reported by 52 percent of patients in the alirocumab 50 mg group, 48 percent of patients in the 75 mg group, 64 percent of patients in the 150 mg group, compared to 32 percent in the placebo group. The most frequently reported TEAEs were nasopharyngitis, injection site reaction, back pain, cystitis and ligament sprain.
“We are delighted with the findings from the first Phase 2 trial with alirocumab in Japanese patients. Not only was alirocumab shown, in this study, to significantly reduce LDL-C in this patient population, the results of this study also demonstrate the potential efficacy of alirocumab at a range of doses,” said Jay Edelberg M.D., Ph.D., Head of the PCSK9 Development and Launch Unit, Sanofi Group.
“Hypercholesterolemia is a growing problem in Japan and many patients are poorly-controlled on statins,” commented George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. “The results from this trial support the efficacy and safety of alirocumab at a range of doses in Japanese patients.”
About the Alirocumab Phase 2 Japanese Study
This multicenter, placebo-controlled Phase 2 study randomized approximately 100 patients with LDL-C greater than or equal to 100 mg/dL receiving lipid-modifying therapy. 25 patients per group were randomized to receive one of three doses of alirocumab dosed subcutaneously every other week (Q2W) — 150 milligrams (mg), 75 mg or 50 mg, or placebo, all in combination with statin therapy.
The primary study endpoint was the percentage change in calculated LDL-C from baseline to Week 12. The secondary study endpoints included absolute change in calculated LDL-C from baseline to Week 12 and percent and absolute changes in other lipid parameters at Week 12.
About PCSK9
PCSK9 is known to be a determinant of circulating LDL levels, as it binds to LDL receptors resulting in their degradation so that fewer are available on liver cells to remove excess LDL-C from the blood. Moreover, statins increase the level of circulating PCSK9, which in turn may reduce the density of LDL-C receptors available to clear LDL-C from the circulation. Blocking the PCSK9 pathway is therefore a potentially novel mechanism for lowering LDL-C.
About alirocumab
Alirocumab is an investigational, fully-human monoclonal antibody that targets and blocks PCSK9. It is administered via subcutaneous injection. By inhibiting PCSK9, a determinant of circulating LDL-C levels in the blood, alirocumab has been shown in pre-clinical studies to increase the number of LDL receptors on hepatocytes, thereby lowering LDL-C.
The investigational agent described above is currently under clinical development, and its safety and efficacy have not been fully evaluated by any regulatory authority.
About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (SAN) and in New York (SNY).
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York, that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, asthma, and atopic dermatitis. For additional information about the company, please visit www.regeneron.com.
SOURCE: Regeneron Pharmaceuticals
Post Views: 160
